PPARG and Parkinson disease: In particular, in MPTP and 6-OHDA models of PD, preclinical studies have shown that different PPARγ agonists reduce neuronal cell death, microglial activation, and the DA level in the hippocampus and SNpc [15,19,52,53,54].